Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells

2 Jan 2020

Abstract excerpt

PURPOSE: Although tamoxifen remains the frontline treatment for ERα-positive breast cancers, resistance to this drug limits its clinical efficacy. Most tamoxifen-resistant patients retain ERα expression which may support growth and progression of breast cancers. Therefore, we investigated epigenetic regulation of ERα that may provide a rationale for targeting ERα in these patients. METHODS: Expression levels of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Epigenetics and DNA Methylation
Share to Estrogen and related hormone effects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31897900
DOI: 10.1007/s10549-019-05517-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cellsPMID 31897900Read ↗

A New Role for ERα: Silencing via DNA Methylation of Basal, Stem Cell, and EMT GenesSemantic proximity Read ↗

Inhibition of O-GlcNAc transferase activates tumor-suppressor gene expression in tamoxifen-resistant breast cancer cellsSemantic proximity Read ↗

STAT 1 facilitates oestrogen receptor α transcription and stimulates breast cancer cell proliferationSemantic proximity Read ↗

Endocrine therapy-specific lineage and partial epithelial-mesenchymal reprogramming defines divergent resistant cell-states in ER+ breast cancerSemantic proximity Read ↗

PML1-Mediated Feedforward Loop Through PI3K and MAPK Axes Drives Endocrine ResistanceSemantic proximity Read ↗

Loss function of tumor suppressor FRMD8 confers resistance to tamoxifen therapy via a dual mechanismSemantic proximity Read ↗

Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancerSemantic proximity Read ↗

Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancerSemantic proximity Read ↗

PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancerSemantic proximity Read ↗

MLL3 is a de novo cause of endocrine therapy resistance.Semantic proximity Read ↗

Novel insights into the molecular mechanisms of endocrine resistance in ERα positive breast cancerSemantic proximity Read ↗

ELOVL2: a novel tumor suppressor attenuating tamoxifen resistance in breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.